Geulah Livshits
Stock Analyst at Chardan Capital
(3.89)
# 657
Out of 4,981 analysts
220
Total ratings
41.36%
Success rate
13.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $219 → $216 | $155.71 | +38.72% | 13 | Aug 22, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 | $3.22 | +241.61% | 21 | Aug 20, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $20 → $15 | $5.38 | +178.81% | 10 | Aug 15, 2025 | |
| MGX Metagenomi | Maintains: Buy | $12 → $11 | $1.82 | +504.40% | 7 | Aug 15, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $50 → $60 | $54.63 | +9.83% | 2 | Aug 15, 2025 | |
| IMRX Immuneering | Maintains: Buy | $13 | $7.86 | +65.39% | 13 | Aug 14, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $15 | $5.49 | +173.22% | 8 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $9 → $10 | $3.02 | +231.13% | 14 | Aug 12, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $25 | $6.80 | +267.65% | 12 | Aug 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $68 → $60 | $11.57 | +418.58% | 15 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $10 | $4.01 | +149.38% | 6 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $1.36 | +782.35% | 10 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $2.27 | +781.06% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $1.20 | +650.00% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 | $57.84 | +41.77% | 15 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 | $6.95 | +1,626.62% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.50 | +1,106.76% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.67 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.33 | +459.35% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $5.70 | +338.60% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.91 | +528.27% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $23.88 | +771.02% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.16 | +1,285.28% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $9.09 | +890.10% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $4.21 | -4.99% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $3.07 | +877.20% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $9.48 | +89.87% | 1 | Oct 27, 2020 |
Krystal Biotech
Aug 22, 2025
Maintains: Buy
Price Target: $219 → $216
Current: $155.71
Upside: +38.72%
Rocket Pharmaceuticals
Aug 20, 2025
Maintains: Buy
Price Target: $11
Current: $3.22
Upside: +241.61%
Lexeo Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $20 → $15
Current: $5.38
Upside: +178.81%
Metagenomi
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.82
Upside: +504.40%
Palvella Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $50 → $60
Current: $54.63
Upside: +9.83%
Immuneering
Aug 14, 2025
Maintains: Buy
Price Target: $13
Current: $7.86
Upside: +65.39%
Solid Biosciences
Aug 14, 2025
Maintains: Buy
Price Target: $15
Current: $5.49
Upside: +173.22%
Taysha Gene Therapies
Aug 12, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $3.02
Upside: +231.13%
4D Molecular Therapeutics
Aug 12, 2025
Maintains: Buy
Price Target: $25
Current: $6.80
Upside: +267.65%
Intellia Therapeutics
Aug 11, 2025
Maintains: Buy
Price Target: $68 → $60
Current: $11.57
Upside: +418.58%
Aug 8, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $4.01
Upside: +149.38%
Aug 8, 2025
Maintains: Buy
Price Target: $12
Current: $1.36
Upside: +782.35%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $2.27
Upside: +781.06%
Aug 7, 2025
Maintains: Buy
Price Target: $9
Current: $1.20
Upside: +650.00%
Aug 5, 2025
Maintains: Buy
Price Target: $82
Current: $57.84
Upside: +41.77%
Jun 24, 2025
Maintains: Buy
Price Target: $120
Current: $6.95
Upside: +1,626.62%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.50
Upside: +1,106.76%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.67
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.33
Upside: +459.35%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $5.70
Upside: +338.60%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $1.91
Upside: +528.27%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $23.88
Upside: +771.02%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.16
Upside: +1,285.28%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $9.09
Upside: +890.10%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $4.21
Upside: -4.99%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $3.07
Upside: +877.20%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $9.48
Upside: +89.87%